Gracell Biotechnologies Inc.
NASDAQ: GRCL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Wei Cao BM,
- Employees
- 314
- Headquarters
- Suzhou, China
- IPO year
- 2021
- Market cap
- $198.0M
- Website
- https://www.gracellbio.com
Loading GRCL…
Loading profile data…Frequently asked questions about GRCL
What does Gracell Biotechnologies Inc. (GRCL) do?
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BC...
Where does GRCL trade?
Gracell Biotechnologies Inc. (GRCL) trades on the NASDAQ Global Select.
What sector is GRCL in?
Gracell Biotechnologies Inc. (GRCL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Gracell Biotechnologies Inc.?
Wei Cao BM, is the chief executive officer of Gracell Biotechnologies Inc. (GRCL).
Where is Gracell Biotechnologies Inc. headquartered?
Gracell Biotechnologies Inc. is headquartered in China.
Does GRCL pay a dividend?
Gracell Biotechnologies Inc. (GRCL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GRCL go public?
Gracell Biotechnologies Inc. (GRCL) completed its initial public offering in 2021.
Is GRCL an ADR?
Yes — GRCL is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Gracell Biotechnologies Inc. reporting and dividends follow the underlying issuer.